Sinovac Provides Support to China's Ministry of Health to Aid Earthquake Victims
Posted on: Wednesday, 21 May 2008, 15:00 CDT
BEIJING, May 21 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. , a leading provider of vaccines in China, today announced that it is providing immediate support to China's Ministry of Health following the May 12th earthquake in Sichuan province. The assistance is intended to support disease control efforts and includes 50,000 doses of Healive(R), Sinovac's internally developed and commercialized hepatitis A vaccine, as well as RMB 500,000 and the expertise of Sinovac's disease control experts. In addition, Sinovac's employees contributed RMB 110,000 for the Ministry of Health's disease control initiatives.
The Healive supply will be applied to the disaster zone, where the water supply infrastructure has been badly damaged. According to the WHO, hepatitis A is associated with inadequate water supplies and poor sanitation and hygiene, leading to infection and inflammation of the liver. Sinovac believes, because of economies of scale achieved in its Healive manufacturing process, that it can easily make this donation while still being able to meet any additional demand.
Mr. Weidong Yin, Chairman, President and CEO, stated, "While many Chinese companies and citizens are mobilizing to aid the victims of the May 12th earthquake, Sinovac is proud to provide assistance, vaccine donations and financial resources for disease control. Our close coordination with the Ministry of Health on this undertaking underscores our team's extensive scientific and field knowledge about disease prevention and their ability to provide advisory services to raise awareness about disease prevention and the benefits of vaccine administration."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com/ . To be added to our distribution list, please email: info@sinovac.com .
For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 Ext. 871 Fax: +86-10-6296-6910 Email: info@sinovac.com Investors/Media: Stephanie Carrington/Janine McCargo The Ruth Group Tel: 646-536-7017/7033 Email: scarrington@theruthgroup.com Email: jmccargo@theruthgroup.com
Sinovac Biotech Ltd.
CONTACT: Helen G. Yang of Sinovac Biotech Ltd. at +86-10-8289-0088 x871,or fax +86-10-62966910, or info@sinovac.com; investors and media shouldcontact Stephanie Carrington or Janine McCargo of The Ruth Group at The RuthGroup +1-646-536-7017/7033, or scarrington@theruthgroup.com orjmccargo@theruthgroup.com
Web Site: http://www.sinovac.com/
Source: PRNewswire
Related Articles
- PA Department of Health Continues to Offer Free H1N1 Flu Vaccine on Saturdays at 60 State Health Centers
- Focusing On HIV Treatment Helps Control Concurrent Hepatitis B Infection
- Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
- Report Finds Community-Based Disease Prevention Saves California Money and Improves Californians' Health
- The Influenza Vaccine Is The Fastest Growing In The Adult Vaccine Segment Followed By The Hepatitis Vaccine
- Sinovac Enters Purchase Agreement With Beijing Public Health Bureau for Anflu, Sinovac's Seasonal Influenza Vaccine
- Preliminary Result of Phase I Clinical Trial Shows That Sinovac's Pandemic Influenza Vaccine (H5N1) Has High Safety and Immunogenicity Profile
- Bird Flu Well Under Control in China: Health Minister
- Hepatitis A Vaccine not Widely Used for Hepatitis C Patients
- SW China Province Vaccinates Pigs to Control Epidemic
 |
 |
User Comments (0)
RSS Feeds